- Home
- ARQT vs VMEO Comparison
ARQT vs VMEO Comparison
Compare ARQT & VMEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARQT
- VMEO
- Stock Information
- Founded
- ARQT 2016
- VMEO 2004
- Country
- ARQT United States
- VMEO United States
- Employees
- ARQT N/A
- VMEO N/A
- Industry
- ARQT Biotechnology: Pharmaceutical Preparations
- VMEO Computer Software: Prepackaged Software
- Sector
- ARQT Health Care
- VMEO Technology
- Exchange
- ARQT Nasdaq
- VMEO Nasdaq
- Market Cap
- ARQT 1.7B
- VMEO 668.9M
- IPO Year
- ARQT 2020
- VMEO N/A
- Fundamental
- Price
- ARQT $13.78
- VMEO $3.93
- Analyst Decision
- ARQT Strong Buy
- VMEO Buy
- Analyst Count
- ARQT 6
- VMEO 4
- Target Price
- ARQT $18.80
- VMEO $7.35
- AVG Volume (30 Days)
- ARQT 2.0M
- VMEO 1.7M
- Earning Date
- ARQT 08-13-2025
- VMEO 08-04-2025
- Dividend Yield
- ARQT N/A
- VMEO N/A
- EPS Growth
- ARQT N/A
- VMEO N/A
- EPS
- ARQT N/A
- VMEO 0.10
- Revenue
- ARQT $212,819,000.00
- VMEO $415,130,000.00
- Revenue This Year
- ARQT $61.15
- VMEO $3.90
- Revenue Next Year
- ARQT $37.98
- VMEO $6.17
- P/E Ratio
- ARQT N/A
- VMEO $38.56
- Revenue Growth
- ARQT 100.03
- VMEO N/A
- 52 Week Low
- ARQT $7.86
- VMEO $3.45
- 52 Week High
- ARQT $17.75
- VMEO $7.90
- Technical
- Relative Strength Index (RSI)
- ARQT 46.51
- VMEO 32.47
- Support Level
- ARQT $13.51
- VMEO $3.85
- Resistance Level
- ARQT $14.31
- VMEO $4.08
- Average True Range (ATR)
- ARQT 0.61
- VMEO 0.12
- MACD
- ARQT -0.01
- VMEO 0.00
- Stochastic Oscillator
- ARQT 46.95
- VMEO 16.00
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
About VMEO Vimeo Inc.
Vimeo Inc is the all-in-one video software solution, providing the full breadth of video tools through a software-as-a-service model. The comprehensive and cloud-based tools of the company empower its users to create, share, collaborate and communicate with video on a single, turnkey platform. The company derives its revenue from SaaS subscription fees paid by customers for subscription plans.